SPK Acquisition Corp

SPK Acquisition Corp. operates as a blank check company. It is a special purpose acquisition company which was incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 31, 2020 and is headquartered in Shanghai, China.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. (“Varian Bio”), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. (“SPK”) (NASDAQ: SPK), a special purpose acquisition company (“SPAC”), today announced a joint presentation to discuss the proposed transaction and provide a corporate update.

Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update

NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. (“Varian Bio”), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. (“SPK”) (NASDAQ: SPK), a special purpose acquisition company (“SPAC”), today announced it has entered into a definitive merger agreement for a business combination that will result in Varian Bio becoming a publicly traded company. Varian Bio is developing a high-potency, specific atypical protein kinase C iota (“aPKCi”) inhibitor that has the potential to be best-in-class as a treatment for various oncology indications with an initial focus on basal cell carcinoma (BCC) and molecularly targeted solid tumors.

Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.

NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- SPK Acquisition Corp. ("the Company" or "SPK") (NASDAQ: SPKAU), a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced that holders of the Company's units may elect to separately trade the common stock and rights included in its units commencing on or about July 23, 2021.

SPK Acquisition Corp. Announces that Common Stock and Rights to Commence Separate Trading on or about July 23, 2021

NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- SPK Acquisition Corp. (NASDAQ: SPKAU, the "Company") announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units will be listed on The NASDAQ Capital Market ("NASDAQ") and trade under the ticker symbol "SPKAU" beginning tomorrow, June 8, 2021. Each unit consists of one share of common stock and one right to receive one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the common stock and rights will be listed on NASDAQ under the symbols "SPK" and "SPKAR," respectively.

SPK Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering

News for SPK Acquisition Corp Stock (SPKAU)